GeneDx Holdings Corp. (NASDAQ:WGS) is Bosun Asset Management LLC's 2nd Largest Position

Bosun Asset Management LLC lessened its holdings in GeneDx Holdings Corp. (NASDAQ:WGS - Free Report) by 31.1% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 117,274 shares of the company's stock after selling 52,860 shares during the quarter. GeneDx accounts for approximately 3.9% of Bosun Asset Management LLC's holdings, making the stock its 2nd largest holding. Bosun Asset Management LLC owned 0.43% of GeneDx worth $9,014,000 as of its most recent SEC filing.

A number of other large investors have also modified their holdings of WGS. BNP Paribas Financial Markets acquired a new stake in GeneDx during the 4th quarter worth about $4,349,000. Ameriprise Financial Inc. acquired a new position in GeneDx in the 4th quarter worth approximately $2,645,000. Freestone Grove Partners LP purchased a new position in GeneDx during the 4th quarter worth approximately $445,000. Comerica Bank acquired a new stake in GeneDx during the 4th quarter valued at approximately $50,000. Finally, Regal Partners Ltd purchased a new stake in shares of GeneDx in the 4th quarter valued at $769,000. Hedge funds and other institutional investors own 61.72% of the company's stock.

Insider Transactions at GeneDx

In other GeneDx news, CFO Kevin Feeley sold 388 shares of the stock in a transaction dated Tuesday, April 29th. The shares were sold at an average price of $113.09, for a total value of $43,878.92. Following the completion of the sale, the chief financial officer now owns 3,337 shares in the company, valued at approximately $377,381.33. This represents a 10.42 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Katherine Stueland sold 1,078 shares of the business's stock in a transaction that occurred on Thursday, March 13th. The stock was sold at an average price of $89.44, for a total value of $96,416.32. Following the transaction, the chief executive officer now owns 6,674 shares in the company, valued at approximately $596,922.56. This represents a 13.91 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 139,390 shares of company stock valued at $13,043,288. Corporate insiders own 27.30% of the company's stock.

Analysts Set New Price Targets

Several brokerages have weighed in on WGS. Jefferies Financial Group raised GeneDx from a "hold" rating to a "buy" rating and set a $80.00 price target on the stock in a research report on Friday. The Goldman Sachs Group raised their target price on GeneDx from $70.00 to $80.00 and gave the stock a "neutral" rating in a report on Wednesday, February 19th. TD Securities decreased their price target on GeneDx from $135.00 to $110.00 and set a "buy" rating for the company in a report on Thursday, May 1st. Finally, Wells Fargo & Company dropped their price objective on shares of GeneDx from $105.00 to $78.00 and set an "equal weight" rating on the stock in a research note on Thursday, May 1st. Two equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $86.57.

GeneDx Price Performance

WGS traded up $2.57 during trading on Friday, hitting $58.93. The company's stock had a trading volume of 1,575,298 shares, compared to its average volume of 739,796. The company has a current ratio of 2.40, a quick ratio of 2.27 and a debt-to-equity ratio of 0.25. The firm has a market capitalization of $1.65 billion, a price-to-earnings ratio of -30.07 and a beta of 1.96. The business's fifty day simple moving average is $90.42 and its 200 day simple moving average is $82.63. GeneDx Holdings Corp. has a twelve month low of $19.16 and a twelve month high of $117.75.

GeneDx (NASDAQ:WGS - Get Free Report) last released its quarterly earnings results on Wednesday, April 30th. The company reported $0.28 earnings per share for the quarter, topping the consensus estimate of $0.11 by $0.17. The firm had revenue of $87.12 million during the quarter, compared to the consensus estimate of $79.90 million. GeneDx had a negative net margin of 17.12% and a positive return on equity of 3.33%. On average, equities research analysts forecast that GeneDx Holdings Corp. will post 0.97 EPS for the current fiscal year.

GeneDx Profile

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.